| Abstrakt: |
Keywords: Angiotensin II Receptor Antagonist; Arthritis; Biphenyl Compounds; Emerging Technologies; Health and Medicine; Hydrocarbons; Losartan; Musculoskeletal Diseases and Conditions; Nanofibers; Nanotechnology; Osteoarthritis EN Angiotensin II Receptor Antagonist Arthritis Biphenyl Compounds Emerging Technologies Health and Medicine Hydrocarbons Losartan Musculoskeletal Diseases and Conditions Nanofibers Nanotechnology Osteoarthritis 2023 FEB 23 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Investigators publish new report on osteoarthritis. According to news originating from Vail, Colorado, by NewsRx correspondents, research stated, "The central pathologic feature of osteoarthritis (OA) is the progressive loss of articular cartilage, which has a limited regenerative capacity. [Extracted from the article] |
